Related Experiment Videos
[Anticoagulation in critically ill patient]
1Klinische Abteilung für Allgemeine und Chirurgische Intensivmedizin, Universitätsklinik für Anästhesie und Allgemeine Intensivmedizin, Medizinische Universität Innsbruck, Innsbruck, Austria. dietmar.fries@i-med.ac.at
Abstract:
Incidence of deep vein thrombosis in critically ill patients depends on the underlying disease but may be as high as 60%. In patients with severe sepsis or septic shock, Surviving Sepsis Campaign clearly recommends administering anticoagulation in the absence of specific contraindications. The article discusses risk factor for thromboembolic events in critical illness, non-pharmacological and pharmacological thrombosis prophylaxis as well as means of monitoring anticoagulation. Considering the ideal route of administration in intensive care patients, peripheral vasoconstriction, edema, shock, and administration of catecholamines may reduce bioavailability and efficacy of subcutaneous administration of low molecular weight heparin (LMWH). Dosing of the direct thrombin inhibitor argatroban depends on the severity of illness (SAPS II-score) and is up to 10-times lower than in patients without critical illness.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management